Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?

Bullous pemphigoid, mucous membrane pemphigoid, and pemphigus vulgaris are different cutaneous autoimmune blistering diseases, with complex pathogenic mechanisms. In all of them, a type‐2 response is thought to have a central role. Interleukin 4 and Interleukin 13 are crucial cytokines in type‐2 response. Treatment of these conditions is often challenging. Dupilumab, a recombinant fully human IgG4 monoclonal antibody with binding specificity to human interleukin‐4 receptor IL‐4Rα, has the potential to inhibit both IL‐4 and IL‐13. We propose IL‐4Rα as a theoretical drug target for cutaneous autoimmune bullous diseases.